Key Considerations for Liver Transplant Decisions in Hepatocellular Carcinoma Patients
Latest Trends in Liver Transplantation for Hepatocellular Carcinoma
When deciding on liver transplants for hepatocellular carcinoma (HCC) patients, the 'type of cancer' is now considered more important than tumor size. Recent discussions include new guidelines for transarterial chemoembolization and targeted therapy selection, as well as revisions to hepatitis B treatment protocols.
Changes in Liver Transplant Selection Criteria
A recent column emphasized that for HCC patients undergoing liver transplantation, 'what type of cancer it is' matters more than 'how large the tumor is.' This highlights the need to develop treatment plans based on cancer type and progression rather than relying solely on size-based criteria.
The Korean Society of Hepatology will revise its guidelines for chronic hepatitis B and cirrhosis in June 2026, changing the treatment focus from 'viral load' to 'viral DNA levels.' This shift marks a new era where viral suppression becomes central to treatment planning.
New Drug Development and Improved Survival Rates
Geosell's newly developed drug 'Immunocel L-C' has shown promising results in reducing cancer recurrence after liver transplants. According to reports dated September 11, 2026, the drug improved survival rates and reduced post-transplant recurrence risks for HCC patients.
Boramae Hospital recruited Professor Seo Kyung-seok as an expert in HCC and liver transplantation in February 2025. Gangdong Kyunghee University Hospital received 'Top Excellence' recognition in HCC and breast cancer appropriateness evaluations in August 2025, reflecting the growing expertise of domestic hospitals in this field.
According to a September 8, 2026 report, expanded liver transplant facilities have opened new treatment opportunities for cancer patients. There have also been reports of family members donating part of their liver to siblings—such as a 29-year-old man who donated his liver to his brother battling cancer.
Medical Technology Innovations
An AI model designed to support the decision-making process for optimal surgical methods in hepatocellular carcinoma was completed in December 2025. This tool aims to assist medical professionals during complex surgeries requiring precise techniques and clear judgment.
A multi-disciplinary approach in HCC treatment, introduced in March 2026, has improved outcomes by considering patients' complex conditions when developing comprehensive treatment plans.
According to a March 22, 2023 report, South Korea's xenotransplantation technology for liver transplants is ranked among the world's best. Professor Huang Shin from Seoul Asan Hospital was elected as the new president of the Korean Transplant Society on December 20, 2023.
As emphasized in a September 8, 2026 report, HCC often progresses silently, making regular check-ups crucial for improving survival rates. Early detection through routine screenings is vital since symptoms are typically absent in early stages.

Revised Guidelines for Hepatocellular Carcinoma Treatment
The guidelines for chronic hepatitis B and cirrhosis were comprehensively revised in June 2026. This change shifts the treatment focus from 'viral infection status' to 'viral DNA levels,' marking a new era where viral suppression is central to treatment planning.
On June 16, 2026, the Korean Society of Hepatology revised its hepatitis B guidelines, declaring a new era centered on HBV DNA levels. This represents a shift from merely determining infection status to developing tailored treatment plans based on viral suppression levels.
Increasing Trust in Liver Transplantation for HCC Patients
According to a March 17, 2025 report, liver transplantation for HCC is no longer something patients need to fear. This reflects increased confidence in the safety and effectiveness of liver transplant procedures.
A September 11, 2026 report confirmed that Immunocel L-C by Geosell demonstrated improved survival rates after liver transplants for HCC patients. The drug is expected to reduce post-transplant recurrence risks and enhance treatment outcomes.
Importance of Diagnosis and Prevention
HCC often progresses silently, making regular check-ups essential for improving survival rates. According to a September 8, 2026 report, early detection through routine screenings is crucial as symptoms are typically absent in the initial stages.
Since April 2018, ultrasound examinations of the upper abdomen (including liver and gallbladder) have been covered by health insurance. This expansion has improved access to early diagnosis, increasing the likelihood of detecting HCC at an earlier stage.
Strengthening Hospital Expertise
Yangsan Busan University Hospital received consecutive top ratings in cancer appropriateness evaluations on August 29, 2023. Kyunghee University Hospital achieved notable results through patient-centered care and adoption of cutting-edge medical technology during its 50th-anniversary celebration in July 2021.
Boramae Hospital recruited Professor Seo Kyung-seok as an HCC and liver transplantation expert in February 2025, enhancing the hospital's specialized capabilities. Gangdong Kyunghee University Hospital received 'Top Excellence' recognition in HCC and breast cancer appropriateness evaluations in August 2025.
Advancements in Liver Transplant Technology
According to a March 22, 2023 report, South Korea's xenotransplantation technology for liver transplants is considered among the world's best. Professor Huang Shin from Seoul Asan Hospital was elected as the new president of the Korean Transplant Society on December 20, 2023.
As reported on September 8, 2026, there have been cases where siblings donated part of their liver to treat HCC—such as a 29-year-old man who donated his liver to his brother battling cancer. These family donation cases are being recognized for expanding treatment opportunities.
Changes in Medical Policy
The June 2026 revision of chronic hepatitis B and cirrhosis guidelines, which changed the treatment focus to 'viral DNA levels,' signifies a shift toward viral suppression as the core of treatment. This change moves beyond simply determining infection status to developing tailored treatment plans based on viral load.
Emphasis on Regular Check-ups
The importance of regular check-ups for HCC has been repeatedly emphasized across multiple reports. As stated in a September 8, 2026 report, early detection through routine screenings is essential since symptoms are typically absent in the initial stages.
Key Information for Patients to Remember
When deciding on liver transplants for HCC patients, remember that 'the type of cancer' matters more than tumor size. This means treatment plans should be developed based on cancer type and characteristics rather than just size.
The revised hepatitis B guidelines now focus on 'viral DNA levels.' Patients should understand that a new era of treatment centered around HBV DNA levels has begun.
Immunocel L-C has demonstrated effectiveness in reducing recurrence after liver transplants for HCC patients. This drug is being recognized as an important new medication contributing to improved survival rates.
Frequently Asked Questions
Why is the type of cancer more important than size when considering liver transplantation for HCC patients?
Treatment plans should be developed based on cancer type and characteristics. Relying solely on tumor size may not lead to appropriate treatment, so evaluating cancer type is essential.
What are the key changes in the revised hepatitis B guidelines?
The treatment focus has shifted from 'infection status' to 'viral DNA levels.' This change enables tailored treatment plans based on viral suppression levels.
Which new drug helps improve survival rates after liver transplantation for HCC patients?
Geosell's 'Immunocel L-C' has demonstrated effectiveness in reducing recurrence and improving survival rates after liver transplants for HCC patients, as confirmed by reports from September 11, 2026.
Frequently Asked Questions
The field of hepatocellular carcinoma (HCC) treatment and liver transplantation has seen significant changes recently. Key developments include considering tumor type over size in transplant selection, the new era of hepatitis B treatment centered on viral DNA levels, and improved survival rates through drugs like Immunocel L-C. Additionally, early detection through regular check-ups and a multi-disciplinary approach have become increasingly important. Domestic hospitals are strengthening their expertise, and technological advancements are improving treatment outcomes.
Given that HCC often progresses silently, regular check-ups are essential. The expansion of health insurance coverage for upper abdominal ultrasound examinations since April 2018 represents an important change in early detection accessibility, which should be widely recognized.
South Korea's xenotransplantation technology is ranked among the world's best, and family donation cases are increasing, expanding treatment opportunities. With continued drug development and medical technological advances, future improvements in HCC patient outcomes are expected.
You can explore more articles on similar topics at once.
View Related ArticlesFAQ
Why is the type of cancer more important than size when considering liver transplantation for HCC patients?
Treatment plans should be developed based on cancer type and characteristics. Relying solely on tumor size may not lead to appropriate treatment, so evaluating cancer type is essential.
What are the key changes in the revised hepatitis B guidelines?
The treatment focus has shifted from 'infection status' to 'viral DNA levels.' This change enables tailored treatment plans based on viral suppression levels.
Which new drug helps improve survival rates after liver transplantation for HCC patients?
Geosell's 'Immunocel L-C' has demonstrated effectiveness in reducing recurrence and improving survival rates after liver transplants for HCC patients, as confirmed by reports from September 11, 2026.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 심철종 간암 환자, 간 이식 결정 시 고려해야 할 사항